Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.52 is in line with its 5-year average of -2.29, near the low end of its 5-year range (-3.73–0.48).
28.21% above its 12-month average of -3.51.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.55.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:08:15.736Z. Historical observations retain their original dates. Historical series through 2022-11-03.
EARNINGS PER SHARE (EPS)
-2.52
EARNINGS PER SHARE (EPS) AVG TTM
-3.51
EARNINGS PER SHARE (EPS) AVG 3Y
-3.12
EARNINGS PER SHARE (EPS) AVG 5Y
-2.29
EARNINGS PER SHARE (EPS) AVG 10Y
-2.61
EARNINGS PER SHARE (EPS) AVG 15Y
-2.37
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.21%
CURRENT VS 3Y AVG
+19.10%
CURRENT VS 5Y AVG
-9.96%
CURRENT VS 10Y AVG
+3.62%
CURRENT VS 15Y AVG
-6.20%
CURRENT VS 20Y AVG
N/A
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
Earnings Per Share (EPS)
-2.52
TTM Avg
-3.51
3Y Avg
-3.12
5Y Avg
-2.29
Market Cap
$1.54B
Earnings Per Share (EPS)
4.10
TTM Avg
2.19
3Y Avg
2.59
5Y Avg
2.64
Market Cap
$1.52B
Earnings Per Share (EPS)
25.28
TTM Avg
10.68
3Y Avg
-22.38
5Y Avg
-5.21
Market Cap
$1.57B
Earnings Per Share (EPS)
-3.36
TTM Avg
-0.89
3Y Avg
-1.69
5Y Avg
-1.77
Market Cap
$1.50B
Earnings Per Share (EPS)
0.38
TTM Avg
-0.16
3Y Avg
-0.18
5Y Avg
-0.35
Market Cap
$1.48B
Earnings Per Share (EPS)
2.44
TTM Avg
1.82
3Y Avg
1.13
5Y Avg
1.18
Market Cap
$1.47B
Earnings Per Share (EPS)
-3.04
TTM Avg
-3.32
3Y Avg
-2.31
5Y Avg
-2.31
Market Cap
$1.47B
Earnings Per Share (EPS)
-1.00
TTM Avg
-0.77
3Y Avg
-0.59
5Y Avg
-0.43
Market Cap
$1.61B
Earnings Per Share (EPS)
0.84
TTM Avg
0.16
3Y Avg
0.00
5Y Avg
0.42
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | -2.52 | -3.51 | -3.12 | -2.29 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 4.10 | 2.19 | 2.59 | 2.64 |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 25.28 | 10.68 | -22.38 | -5.21 |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -3.36 | -0.89 | -1.69 | -1.77 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 0.38 | -0.16 | -0.18 | -0.35 |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 2.44 | 1.82 | 1.13 | 1.18 |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.47B | -3.04 | -3.32 | -2.31 | -2.31 |
| GH Research PLC (GHRS)vs › | $1.47B | -1.00 | -0.77 | -0.59 | -0.43 |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 0.84 | 0.16 | 0.00 | 0.42 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.61B | -2.67 | -2.43 | -2.07 | -2.07 |
Trailing EPS (TTM)
$-2.52
Forward EPS (Est.)
$-1.99
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.29 |
| 2024-12-31 | -3.73 |
| 2023-12-31 | -2.98 |
| 2022-12-31 | -2.46 |
| 2021-12-31 | 0.48 |
| 2020-12-31 | -1.77 |
| 2019-12-31 | -1.84 |
| 2018-12-31 | -2.92 |
| 2017-12-31 | -2.90 |
| 2016-12-31 | -3.04 |
| 2015-12-31 | -4.31 |
| 2014-12-31 | -2.07 |
| 2013-12-31 | -1.77 |
| 2012-12-31 | -0.14 |
| 2011-12-31 | 0.00 |
